These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

891 related articles for article (PubMed ID: 16919870)

  • 1. Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition.
    Spicer J; Ellis P
    Cancer Lett; 2007 Apr; 248(2):165-74. PubMed ID: 16919870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
    Mouridsen HT; Robert NJ
    Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
    Monnier AM
    Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review.
    Poole R; Paridaens R
    Curr Opin Oncol; 2007 Nov; 19(6):564-72. PubMed ID: 17906453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy.
    Wheler J; Johnson M; Seidman A
    Semin Oncol; 2006 Dec; 33(6):672-80. PubMed ID: 17145347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer.
    Dodwell D; Williamson D
    Cancer Treat Rev; 2008 Apr; 34(2):137-44. PubMed ID: 18006236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
    Goss PE
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer.
    Chlebowski RT
    Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():25-34. PubMed ID: 19101792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
    Kaufmann M; Rody A
    Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):146-54. PubMed ID: 16621229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
    Wardley AM
    Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are aromatase inhibitors superior to antiestrogens?
    Howell A; Buzdar A
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):237-47. PubMed ID: 15860266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer.
    van de Velde CJ; Verma S; van Nes JG; Masterman C; Pritchard KI
    Cancer Treat Rev; 2010 Feb; 36(1):54-62. PubMed ID: 19944537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings.
    Ingle JN
    Clin Cancer Res; 2005 Jan; 11(2 Pt 2):900s-5s. PubMed ID: 15701884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.
    Buzdar A; Chlebowski R; Cuzick J; Duffy S; Forbes J; Jonat W; Ravdin P
    Curr Med Res Opin; 2006 Aug; 22(8):1575-85. PubMed ID: 16870082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant endocrine therapy for postmenopausal women with early breast cancer.
    Ingle JN
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1031s-1036s. PubMed ID: 16467121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant and extended adjuvant use of aromatase inhibitors: reducing the risk of recurrence and distant metastasis.
    Gligorov J; Pritchard K; Goss P
    Breast; 2007 Dec; 16 Suppl 3():S1-9. PubMed ID: 18061455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
    Forbes JF
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
    Buzdar AU; Cuzick J
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1037s-1048s. PubMed ID: 16467122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.